Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 47, Issue 1, pp 73–79 | Cite as

Carbon monoxide inhibits the anticoagulant activity of phospholipase A2 purified from Crotalus adamanteus venom

  • Vance G. NielsenEmail author
Article

Abstract

Snake venom contains a myriad of classes of enzyme which have been investigated for medicinal and toxinological purposes, including phospholipase A2 (PLA2), which is responsible for anticoagulant, myotoxic and neurotoxic effects. Given the importance of PLA2, the purposes of the present investigation were to characterize the coagulation kinetic behavior of a PLA2 purified from Crotalus adamanteus venom (Ca-PLA2) in human plasma with thrombelastography and determine if carbon monoxide could inhibit its activity. Coagulation kinetics were determined in human plasma with a range of Ca-PLA2 activity (0–2 U/ml) via thrombelastography. Then, using carbon monoxide releasing molecule-2 or its inactivated molecule (0 or 100 µM), the vulnerability of Ca-PLA2 activity to carbon monoxide mediated inhibition was assessed. Lastly, the inhibitory response of Ca-PLA2 activity to exposure to carbon monoxide releasing molecule-2 (0–100 µM) was determined. Ca-PLA2 activity degraded the velocity of clot growth and clot strength in an activity dependent, exponential manner. Carbon monoxide inhibited Ca-PLA2 activity in a concentration dependent fashion, with loss of detectable activity at 100 µM of carbon monoxide releasing molecule-2. These findings, while preliminary, open the possibility that other PLA2 contained in snake venom with multiple toxicities (e.g., myotoxin, neurotoxin) may be heme bearing and CO-inhibitable, which have profound potential basic and clinical science implications.

Keywords

Carbon monoxide Phospholipase A2 Thrombelastography Anticoagulation 

Notes

Funding

This investigation was supported by the Department of Anesthesiology, College of Medicine, at the University of Arizona.

Compliance with ethical standards

Conflict of interest

The author declares that he has no conflict of interest.

Ethical approval

This was an in vitro investigation and did not involve any living subjects.

References

  1. 1.
    Sajevic T, Leonardi A, Križaj I (2011) Haemostatically active proteins in snake venoms. Toxicon 57:627–645CrossRefGoogle Scholar
  2. 2.
    Xiao H, Pan H, Liao K, Yang M, Huang C (2017) Snake venom PLA2, a promising target for broad-spectrum antivenom drug development. Biomed Res Int 2017:6592820Google Scholar
  3. 3.
    Krawczyk W, Dmoszynska A, Ledwozyw A, Marczewski K (1996) Human erythropoietin improves blood plasma phospholipids concentration in chronically hemodialyzed patients. Nephron 72:109–110CrossRefGoogle Scholar
  4. 4.
    Hanahan DJ, Nelson DR (1984) Phospholipids as dynamic participants in biological processes. J Lipid Res 25:1528–1535Google Scholar
  5. 5.
    Tan NH, Arunmozhiarasi A (1989) The anticoagulant activity of Malayan cobra (Naja naja sputatrix) venom and venom phospholipase A2 enzymes. Biochem Int 19:803–810Google Scholar
  6. 6.
    Nielsen VG, Frank N, Matika RW (2018) Carbon monoxide inhibits hemotoxic activity of Elapidae venoms: potential role of heme. Biometals 31:51–59CrossRefGoogle Scholar
  7. 7.
    Nielsen VG, Cerruti MA, Valencia OM, Amos Q (2016) Decreased snake venom metalloproteinase effects via inhibition of enzyme and modification of fibrinogen. Biometals 29:913–919CrossRefGoogle Scholar
  8. 8.
    Nielsen VG, Boyer LV (2016) Iron and carbon monoxide attenuate degradation of plasmatic coagulation by Crotalus atrox venom. Blood Coagul Fibrinolysis 27:506–510CrossRefGoogle Scholar
  9. 9.
    Nielsen VG, Bazzell CM (2016) Carbon monoxide attenuates the effects of snake venoms containing metalloproteinases with fibrinogenase or thrombin-like activity on plasmatic coagulation. MedChemComm 7:1973–1979CrossRefGoogle Scholar
  10. 10.
    Dutta S, Chanda A, Kalita B, Islam T, Patra A, Mukherjee AK (2017) Proteomic analysis to unravel the complex venom proteome of eastern India Naja naja: correlation of venom composition with its biochemical and pharmacological properties. J Proteom 156:29–39CrossRefGoogle Scholar
  11. 11.
    Lauridsen LP, Laustsen AH, Lomonte B, Gutiérrez JM (2017) Exploring the venom of the forest cobra snake: toxicovenomics and antivenom profiling of Naja melanoleuca. J Proteom 150:98–108CrossRefGoogle Scholar
  12. 12.
    Petras D, Sanz L, Segura A, Herrera M, Villalta M, Solano D, Vargas M, León G, Warrell DA, Theakston RD, Harrison RA, Durfa N, Nasidi A, Gutiérrez JM, Calvete JJ (2011) Snake venomics of African spitting cobras: toxin composition and assessment of congeneric cross-reactivity of the pan-African EchiTAb-Plus-ICP antivenom by antivenomics and neutralization approaches. J Proteome Res 10:1266–1280CrossRefGoogle Scholar
  13. 13.
    Suntravat M, Langlais PR, Sánchez EE, Nielsen VG (2018) CatroxMP-II: a heme-modulated fibrinogenolytic metalloproteinase isolated from Crotalus atrox venom. Biometals 31:585–593CrossRefGoogle Scholar
  14. 14.
    Fujimoto Y, Akamatsu N, Hattori A, Fujita T (1984) Stimulation of prostaglandin E2 synthesis by exogenous phospholipase A2 and in rabbit kidney medulla slices. Biochem J 218:69–74CrossRefGoogle Scholar
  15. 15.
    Trebien HA, Calixto JB (1989) Pharmacological evaluation of rat paw oedema induced by Bothrops jararaca venom. Agents Actions 26:292–300CrossRefGoogle Scholar
  16. 16.
    Judge RK, Henry PJ, d’Aprile AC, Lynch D, Jelinek GA, Wilce MC, Wilce JA (2002) Identification of PLA(2) and alpha-neurotoxin proteins in the venom of Pseudonaja affinis (dugite). Toxicol Appl Pharmacol 181:184–191CrossRefGoogle Scholar
  17. 17.
    Tsao FH, Keim PS, Henrikson RL (1975) Crotalus adamanteus phospholipase A2-alpha: subunit structure. NH2-terminal sequence, and homology with other phospholipases. Arch Biochem Biophys 167:706–717CrossRefGoogle Scholar
  18. 18.
    Smith CM, Wells MA (1981) A further examination of the active form of Crotalus adamanteus phospholipase A2. Biochim Biophys Acta 663:687–694CrossRefGoogle Scholar
  19. 19.
    da Silva SL, Calgarotto AK, Maso V, Damico DC, Baldasso P, Veber CL, Villar JA, Oliveira AR, Comar M Jr, Oliveira KM, Marangoni S (2009) Molecular modeling and inhibition of phospholipase A2 by polyhydroxy phenolic compounds. Eur J Med Chem 44:312–321CrossRefGoogle Scholar
  20. 20.
    Margres MJ, McGivern JJ, Wray KP, Seavy M, Calvin K, Rokyta DR (2014) Linking the transcriptome and proteome to characterize the venom of the eastern diamondback rattlesnake (Crotalus adamanteus). J Proteomics 96:145–158CrossRefGoogle Scholar
  21. 21.
    Nielsen VG, Bazzell CM (2017) Carbon monoxide releasing molecule-2 inhibition of snake venom thrombin-like activity: novel biochemical “brake”? J Thromb Thrombolysis 43:203–208CrossRefGoogle Scholar
  22. 22.
    Zhang Q, Wang J, Han Y, Xie Q, An L, Bao Y (2007) Identification of a novel thrombin-like phospholipase A2 from Gloydius ussuriensis snake venom. Blood Coagul Fibrinolysis 18:723–729CrossRefGoogle Scholar
  23. 23.
    Nielsen VG (2018) Crotalus atrox venom exposed to carbon monoxide has decreased fibrinogenolytic activity in vivo in rabbits. Basic Clin Pharmacol Toxicol 122:82–86CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of AnesthesiologyThe University of Arizona College of MedicineTucsonUSA

Personalised recommendations